EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia

Xiangmin Wang iD, Bingpei Zhang, Qing Zhang, Hongyuan Zhou, Qian Sun, Yi Zhou, Tianci Li, Dian Zhou, Ziyuan Shen, Jiaoli Zhang, Ping Li, Aibin Liang und 8 weitere

Cancer · 2024-08 · 130 (15) · 2660-2669

DOI: 10.1002/cncr.35316 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 05.04.2024. Verfasst von Xiangmin Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunotherapy, Adoptive, Antigens, CD19, Cytokine Release Syndrome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tocilizumab is commonly used for the management of chimeric antigen receptor (CAR) T‐cell therapy–associated cytokine release syndrome (CRS). However, it remains unknown whether tocilizumab or its dosage affects the efficacy and safety of CAR T‐cell therapy. The objective of this multicenter retrospective study was to explore the impact of tocilizumab on CAR T‐cell therapy.

Methods

In total, 93 patients with B‐cell acute lymphoblastic leukemia (B‐ALL) receiving humanized anti‐CD19 CAR T cells were recruited from May 2016 to November 2022. Forty‐five patients received tocilizumab (tocilizumab group), whereas 48 patients did not (nontocilizumab group). Thirteen patients received >1 dose of tocilizumab. The primary end point was the effect of tocilizumab on the efficacy and safety of CAR T cells. Additionally, proliferation, killing, and cytokine assays of CAR T cells were performed in vitro in the presence of tocilizumab.

Results

The median age of the patients was 33 years, with 47 males and 46 females. Patients in the tocilizumab group showed similar complete response (CR) rate, overall survival (OS), and event‐free survival (EFS) compared with the nontocilizumab group. Compared with patients who received ≤1 dose of tocilizumab, receiving >1 dose of tocilizumab did not affect their CR rate, OS, or EFS. In the tocilizumab group, all patients experienced CRS and 26.7% experienced immune effector cell–associated neurotoxicity syndrome (ICANS). In the nontocilizumab group, 64.6% of patients experienced CRS and 8.3% experienced ICANS. Up to 75% of ICANS and 87.5% of grade ≥3 ICANS occurred in the tocilizumab group. In vitro, tocilizumab did not impair the proliferation and killing effects of CAR T cells.

Conclusions

Tocilizumab does not affect the efficacy of CAR T cells but may increase the likelihood of ICANS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunotherapy, AdoptiveAntigens, CD19Cytokine Release SyndromeReceptors, Chimeric AntigenHumansMaleFemaleAdultRetrospective StudiesMiddle AgedAdolescentYoung AdultChildPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Stichwörter der Autor:innen

acute lymphoblastic leukemiaanti‐CD19chimeric antigen receptor T cellsimmune effector cell–associated neurotoxicity syndrome (ICANS)tocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedAntigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
  • Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
  • Department of Rehabilitation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China.
  • Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Xiangmin Wang, Wei Sang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Wang, X., Zhang, B., Zhang, Q., Zhou, H., Sun, Q., Zhou, Y., Li, T., Zhou, D., Shen, Z., Zhang, J., Li, P., Liang, A., Zhou, K., Han, L., Hu, Y., Yang, Y., Cao, J., Li, Z., Xu, K., & Sang, W. (2024). Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia. Cancer, 130(15), 2660-2669. https://doi.org/10.1002/cncr.35316

Vancouver

Wang X, Zhang B, Zhang Q, Zhou H, Sun Q, Zhou Y, et al. Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia. Cancer. 2024;130(15):2660-2669. doi:10.1002/cncr.35316

BibTeX
@article{Wang2024,
  author = {Wang, Xiangmin and Zhang, Bingpei and Zhang, Qing and Zhou, Hongyuan and Sun, Qian and Zhou, Yi and Li, Tianci and Zhou, Dian and Shen, Ziyuan and Zhang, Jiaoli and Li, Ping and Liang, Aibin and Zhou, Keshu and Han, Lu and Hu, Yongxian and Yang, Yun and Cao, Jiang and Li, Zhenyu and Xu, Kailin and Sang, Wei},
  title = {Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {15},
  pages = {2660--2669},
  doi = {10.1002/cncr.35316}
}
Kostenlos starten →